^
    2d
    Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. (PubMed, Sci Rep)
    However, the randomized phase III POLO trial, upon which this standard is based, did not demonstrate an improved overall survival in patients who received olaparib compared to those who received placebo, highlighting the need for new therapeutic approaches...The model demonstrated high sensitivity to cisplatin plus gemcitabine, but limited efficacy of PARPi monotherapy...The addition of anti-PD1 treatment to PARPi maintenance enhanced tumor regression and prolonged overall survival. These findings provide preclinical support for ongoing clinical trials investigating immunotherapy with PARPi as a maintenance strategy in homologous recombination-deficient PDAC.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • CDX2 (Caudal Type Homeobox 2)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • cisplatin • gemcitabine
    2d
    MEOX2 Enhances DNA Repair and Therapy Resistance in Glioblastoma Stem Cells via PARP1 Interaction. (PubMed, Cancer Lett)
    Using a GLICO (GLioblastoma Cerebral Organoid) model, we show that MEOX2 knockdown impairs tumor growth and increases sensitivity to temozolomide (TMZ)...Consistent with this, MEOX2-depleted cells exhibit reduced PARylation levels and increased sensitivity to the PARP1 inhibitor Talazoparib, highlighting a potential therapeutic vulnerability. Altogether, our findings reveal a previously unrecognized role for MEOX2 in the DNA damage response of GSCs, particularly in promoting survival and recovery after chemotherapy and ionizing radiation. These results also suggest that MEOX2 functions as a partner of PARP1 and may represent a promising therapeutic target in GBM.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • MEOX2 (Mesenchyme Homeobox 2)
    |
    temozolomide • Talzenna (talazoparib)
    3d
    A Single-Arm Prospective Clinical Study of Senaparib as First-Line Maintenance Treatment in HRD-Negative Advanced Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ChiCTR2600117429)
    P=N/A, N=60, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen Universit
    New trial
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Paishuning (senaparib)
    3d
    Efficacy and Safety of Senaparib Maintenance Therapy in Patients with p53-Abnormal Endometrial Carcinoma After Adjuvant Chemotherapy (ChiCTR2600116927)
    P=N/A, N=42, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    carboplatin • paclitaxel • Paishuning (senaparib)
    3d
    Study on the efficacy and safety of QL1706 combined with Senaparib in neoadjuvant therapy for ovarian Cancer: A prospective, single-arm clinical study (ChiCTR2600116175)
    P=N/A, N=20, Not yet recruiting, The Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University
    New trial
    |
    Paishuning (senaparib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Single-Center, Prospective Clinical Study of Senaparib Alone or in Combination with Bevacizumab as First-Line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination-Proficient (HRP) Ovarian Cancer (ChiCTR2600117644)
    P4, N=50, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    3d
    A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ChiCTR2600117526)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Paishuning (senaparib)
    3d
    Multicenter, Single-Arm, Prospective Clinical Study on Senaparib Combined with Bevacizumab for First-Line Maintenance Therapy in Newly Diagnosed BRCA Wild-Type Advanced Ovarian Cancer (ChiCTR2500114463)
    P4, N=62, Recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    3d
    Proton Radiotherapy Combined with PARP Inhibitors versus Proton Radiotherapy Alone for Craniopharyngioma: A Phase II Prospective Randomized Controlled Clinical Trial (ChiCTR2500112360)
    P2, N=88, Not yet recruiting, The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center; The Clinical Technology Research And Development Cent
    New P2 trial
    3d
    Carbon Ion Radiotherapy ± PARP Inhibitor for Skull Base Chordoma: A Phase II Randomized Trial (ChiCTR2500112086)
    P2, N=88, Not yet recruiting, Shanghai Proton and Heavy Ion Center; The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center
    New P2 trial
    3d
    Apigenin modulates cell survival pathways and restores olaparib sensitivity in high-grade serous ovarian cancer cells. (PubMed, Taiwan J Obstet Gynecol)
    API suppresses HGSOC progression by inducing apoptosis, arresting the cell cycle, and modulating survival pathways. It also restores olaparib sensitivity in resistant cells, supporting its potential as an adjuvant therapy to enhance olaparib efficacy in combination treatments.
    Journal • PARP Biomarker
    |
    CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNB1 (Cyclin B1)
    |
    Lynparza (olaparib)
    4d
    Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden. (PubMed, IJU Case Rep)
    Over 3 months, MRI showed further regression of the primary lesion and nodal disease, and PSA and SCC decreased. In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset)
    |
    TMB-H
    |
    Lynparza (olaparib)